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Abstract 
For over a century, psychiatric disorders have been defined by expert opinion and 
clinical observation. The modern DSM has relied on a consensus of experts to define 
categorical syndromes based on clusters of symptoms and signs, and, to some extent, 
external validators such as longitudinal course and response to treatment. In the absence of 
an established etiology, psychiatry has struggled to validate these descriptive syndromes, 
and to define the boundaries between disorders and between normal and pathologic 
variation. Recent advances in genomic research, coupled with large-scale collaborative 
efforts like the Psychiatric Genomics Consortium, have identified hundreds of common and 
rare genetic variations that contribute to a range of neuropsychiatric disorders. At the 
same time, they have begun to address deeper questions about the structure and 
classification of mental disorders: To what extent do genetic findings support or challenge 
our clinical nosology? Are there genetic boundaries between psychiatric and neurologic 
illness? Do the data support a boundary between disorder and normal variation?  Is it 
possible to envision a nosology based on genetically informed disease mechanisms? This 
review provides an overview of conceptual issues and genetic findings that bear on the 
relationships among and boundaries between psychiatric disorders and other conditions. 
We highlight implications for the evolving classification of psychopathology and the 
challenges for clinical translation.  
  
The fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM51) is 
the latest update of a prevailing diagnostic approach to psychiatric illness. The DSM 
consists of symptoms and signs of illness, often complemented by requirements for a 
particular duration and associated distress or disability. Diagnoses are arrived at by 
checklists, with diseases defined by presence of some minimal number of criteria, often 
leaving substantial clinical heterogeneity within disorders. While useful clinically, the 
validity of the DSM boundaries is uncertain. The underlying genetics do not appear to 
precisely support such definitions. The genetic overlap among clinically-defined psychiatric 
syndromes was first demonstrated by family and twin studies. More recently, the work of 
large-scale collaborations, most notably the Psychiatric Genomics Consortium (PGC), has 
enabled DNA-level studies of genetic relationships among psychiatric disorders and related 
traits. Here, we review the state of the genetic structure of psychiatric disorders and its 
implications for psychiatric nosology.  
What does Genetic Epidemiology tell us about the Structure of Psychopathology? 
While the observation that psychiatric disorders ran in families can be traced back to 
antiquity, psychiatric genetics as a scientific discipline arose in the 20th century with the 
first major family, twin, and adoption studies being published, respectively, in 1916 2, 
19283 and 19664. Family studies using modern methodology show substantial familial 
aggregation for all major psychiatric disorders including depression, schizophrenia, bipolar 
disorder, and alcohol dependence, as well as many other syndromes such as panic disorder, 
ADHD, drug abuse, autism, and obsessive-compulsive disorders5. Early twin studies, based 
on hospital or national twin registries, showed evidence of strong heritable effects for 
schizophrenia and bipolar disorder. Later, population-based twin studies showed 
substantial genetic influences on conditions such as major depression, eating and anxiety 
disorders, alcoholism, ADHD and personality disorders6, 7. Adoption studies are more 
difficult to perform, but show heritable risks for schizophrenia (e.g. 8), ADHD (e.g. 9) and 
alcohol dependence (e.g. 10). 
An important question first addressed by family studies was whether there was familial 
overlap among different disorders. When examined with sufficient power, the answer was 
nearly always that a range of psychiatric disorders cluster together in families. Examples 
include bipolar disorder, ADHD and depression; depression and anxiety; mood disorders, 
ADHD and substance abuse; and schizophrenia and schizotypal personality disorder. When 
this question was examined in twin and adoption studies, similar overlaps were found, and 
could be attributed to heritable factors that at least partially overlap (Table 1).  One 
population-based twin study showed that common axis-I and axis-II (personality) 
psychiatric disorders had a coherent underlying genetic structure that reflected just two 
major dimensions, illustrating the extensive sharing of heritable risk factors across 
disorders11. In sum, family and twin studies have long suggested that heritable influences 
on psychopathology transcend diagnostic boundaries; our genes don't seem to have read 
the DSM. 
How Does Molecular Genetics Confirm and Extend Genetic Epidemiologic Findings? 
Studies in the early years of psychiatric molecular genetics tested the parsimonious 
hypothesis that single variants of large effect would underlie the etiology of psychiatric 
disorders, but these were not realized except for rare cases. The method of genome-wide 
association studies (GWAS) gave us a tool for identifying common DNA risk variants (single 
nucleotide polymorphisms, SNPs) along with rare copy-number variants (CNVs). This 
method began to produce results with schizophrenia in 2008 and 2009 12-15 Since then, an 
avalanche of molecular genetic data has generated trustworthy findings for schizophrenia, 
bipolar disorder, major depressive disorder, ADHD and autism. A broad picture of the 
genetic architecture of these disorders is emerging. A large portion of the genetic risk for 
each disorder appears to result from many common SNPs of individually small effect size, 
with additional contributions from relatively rare (but somewhat more penetrant) CNVs. 
With the advent of full genome and exome sequencing, rare single-nucleotide variants 
(SNVs) are also being discovered. One lesson from this work is that very large studies and 
mega-analyses are required to find these variants. Such analyses have become possible 
because of a sea change in the culture of psychiatric genomic research. Investigators across 
the world have come together to share, and often jointly analyze, genetic data through 
large-scale collaborations and consortia, most notably the PGC 16 
(http://www.med.unc.edu/pgc) and iPSYCH (http://ipsych.au.dk). 
The identification by GWAS of common variants reliably associated with psychiatric 
disorders has followed a trajectory similar to that of other common complex biomedical 
disorders17. Early efforts from individual research teams studying relatively small samples 
yielded little fruit, power analyses suggesting the need for much larger samples. Consortia 
were formed to aggregate samples sufficient to reliably detect small effects of common 
variants. The value of such efforts has been made clear by the growing catalogue of 
robustly associated common variants, including more than 100 associated with 
schizophrenia in a PGC analysis of nearly 37,000 cases and more than 113,000 controls18. 
Individual SNPs associated with these diseases explain only a tiny fraction of the heritable 
variance for psychiatric disorders, with most individual risk-predisposing alleles 
associated with odds ratios of 1.1 or less. However, the aggregation of these effects into 
polygenic risk scores (PRSs)19 that capture the additive effects of thousands of SNPs 
accounts for substantially larger fractions of the heritable variance. A range of statistical 
methods allow the estimation of heritability based on genomewide SNPs, often referred to 
as SNP-chip heritability (h2SNP)19. Applied to psychiatric disorders, these methods show that 
the genetic architecture includes a substantial contribution of common variation, though 
the estimates vary from less than 10% (for anxiety disorders and PTSD)20, 21 to more than 
20% (for ADHD, bipolar disorder and schizophrenia) 22, 23 (see Table 1). These estimates 
are lower than those derived from twin studies, in part because h2SNP only includes effects 
due to common variants. 
Genomic studies also show that rare, de novo variations (arising in the gametes or 
embryo) contribute to psychiatric disorders. Thus far, this has most convincingly been 
demonstrated for autism spectrum disorder and schizophrenia. For example, the largest 
analysis of CNV data, by the PGC’s CNV and Schizophrenia Workgroups, comprising more 
than 40,000 subjects, identified eight CNV loci associated with schizophrenia risk24. 
Although these loci were rare (most with a frequency of <0.5% among cases), their effects 
were much larger (ORs ranging from 3.8 to more than 67) than those seen with individual 
common variants.  They include a deletion on chromosome 22 which is the cause of 22qdel 
syndrome (velocardiofacial syndrome) and has long been recognized as carrying a high 
risk for psychosis. The contribution of specific rare SNVs has been harder to establish, 
though large-scale sequencing of the exome has shown that the aggregate burden of rare 
protein-altering variants is elevated in schizophrenia25, autism, 26 and Tourette syndrome. 
27 In addition, mutations in several genes have been associated with autism spectrum 
disorders (e.g. CHD8, SCN2A, SHANK3, GRIN2B)28, 29 and, to a lesser extent, schizophrenia 
(SETD1A)30. 
Genome-wide studies have documented that psychiatric disorders are highly polygenic, 
reflecting a combination of thousands of common variants of individually small effect and 
rarer variants of larger effect. With the disorders best characterized, especially 
schizophrenia, it is increasingly clear that a substantial fraction of genetic risk is the result 
of common SNP variation. As sample sizes grow, additional variants are expected to be 
found. With these discoveries, however, has arisen the challenge of translating these 
molecular findings into insights about etiologic pathways.  
Cross-disorder studies 
Similar to family and twin studies, GWAS first focused on single disorders and then 
examined if risk-conferring variants for one disorder affect risks for others; i.e., pleiotropy. 
(Figure 1 depicts common approaches for evaluating cross-disorder genetic effects). Given 
the large number of human phenotypes and the limited number of genes, it is not 
surprising that pleiotropy is a common phenomenon for many traits and disorders, by no 
means specific to psychiatry31. Among the earliest evidence of shared molecular genetic 
influences across neuropsychiatric disorders were findings that rare CNVs are associated 
with multiple disorders including autism, ADHD, and schizophrenia as well as epilepsy and 
intellectual disability 32. GWAS data have also been used to examine the cross-disorder 
sharing of common variants. For example, the International Schizophrenia Consortium 
reported that a PRS derived from GWAS of schizophrenia was strongly associated with risk 
for bipolar disorder.12. Subsequently, PRS have been used to demonstrate cross-disorder 
genetic overlap of a wide range of psychiatric phenotypes. For example, schizophrenia PRS 
has been associated with psychotic experience 33 and schizoaffective disorder 33 as well as 
related phenotypes such as cognitive ability 34, 35, sensory motor gating 36, working memory 
brain activation (fMRI signal) 37, childhood neurodevelopmental impairments38, major 
depressive disorder39, ADHD and conduct/oppositional defiant disorder40, adolescent 
anxiety disorder41, and PTSD21. 
SNP-chip heritability methods have been extended to estimate the genetic correlation 
between pairs of disorders averaged over all common SNPs. For example, the Cross-
Disorder Group of the PGC reported significant genetic correlations of schizophrenia with 
bipolar disorder (0.68), major depressive disorder (0.43) and autism (0.16), and between 
major depressive disorder and bipolar disorder (0.47) and ADHD (0.32)22 (see Table 1). A 
recent analysis of of the Big Five personality traits further demonstrates specific patterns 
of genetic correlation with psychiatric disorders 42. For a database presenting the many 
statistically significant molecular genetic correlations among psychiatric disorders and 
other phenotypes see LD Hub.43 
Individual common variants have also shown pleiotropic effects across clinically 
distinct disorders39, providing initial clues to a shared biology. Network and pathway 
analyses have pointed to biological pathways that show genetic association across 
diagnostic groups. For example, genes related to calcium channel signaling, histone 
methylation, synaptic function, and immune function have been implicated in both mood 
disorders and schizophrenia.39, 44  
These results suggest that susceptibility to each psychiatric disorder, as currently 
defined by DSM, is influenced by many genetic risk factors and that any given psychiatric 
disorder will share some genetic risk factors with others. This risk-sharing extends beyond 
the genome to the environment, with early developmental insults and trauma implicated in 
risk for several disorders as well. This knowledge has large implications for understanding 
the pathology of psychiatric disorders. However, advances in our statistical methods and a 
range of in vitro and in vivo experimental studies are needed to translate the shared 
genetic and environmental association signals into molecular genetic mechanisms.  
What does it all mean? 
Psychiatric disorders are highly polygenic  
  Family and twin studies, now complemented by molecular genetics, show that genetic 
variation accounts for a substantial portion of the risk for psychiatric disorders, and that 
some of the heritability is shared among disorders. However, many variants remain to be 
discovered, and this will require much larger sample sizes, and additional cross-disorder 
studies. The history of schizophrenia genetics provides a compelling example that simply 
expanding sample size is a winning strategy for driving discovery18. But there are obstacles. 
To make more progress, funders will have to accept the drudgery of “normal science” 
rather than uncritically requiring innovative methods of gene discovery.  
Discovering biological mechanisms from common variants will be challenging.   
Going from a GWAS-associated locus to identifying causal variation underlying the 
association is a challenge, but one that can be overcome with significant effort. A good 
example is Sekar et al.’s 45 study of common variation associated with schizophrenia in the 
major histocompatibility complex, which identified functional alleles of the complement 
component 4 (C4) genes and implicated their role in microglia-mediated synaptic pruning. 
Identifying the causal alleles required complex fine-mapping followed by functional studies 
of gene expression in mouse and human brain, and high-resolution immunohistochemistry.  
Another issue is that most common risk variants individually contribute only a very 
small portion of overall susceptibility to common complex psychiatric disorders.  
Mechanistic studies must eventually integrate the effects of many risk loci. Fortunately, 
powerful new technologies for studying systems genomics and neuroscience (including the 
use of induced pluripotent stem cells, gene-editing methods, and optogenetic interrogation 
of brain circuits) provide new opportunities for dissecting the functional effects of risk 
variants and pathways discovered from them. 46, 47 As the growing catalog of established 
genetic variants converge on biological pathways, new opportunities arise for identifying 
treatment targets. For decades, psychiatric drug development has focused on pathways 
modulated by drugs that had been serendipitously discovered. By moving the focus of drug 
discovery to genetically validated functional pathways, GWAS can point to new “druggable” 
targets, enabling the development of novel therapeutics for specific or cross-diagnostic 
clinical characteristics.48 
Discovering biological mechanisms from rare variants of larger-effect may be easier.  
Unlike common SNPs, rare disease-associated mutations often have direct functional 
consequences, making them especially suitable for mechanistic studies. Some have argued 
the mechanisms discovered via rare variants will not be relevant to the large majority of 
patients, but empirical examples show that a biological pathway implicated by a rare 
variant is relevant to mechanisms implicated by common variation. For example, rare 
variants of PCSK9 cause a rare autosomal dominant familial hypercholesterolemia. Drugs 
that inhibit PCSK9 protein lower cholesterol and are a viable treatment for common forms 
of hypercholesterolemia and atherosclerosis.49 
Genetic studies challenge the DSM paradigm.   
The pervasive cross-disorder heritability of psychiatric disorders challenges the DSM 
paradigm which, from its inception, emphasized hierarchical diagnoses disallowing 
diagnoses of some disorders in the presence of others. Twin data point to genetic 
hierarchies with a general psychopathology factor, internalizing and externalizing factors, 
along with unique sources of heritability for each disorder50. Twin studies have also 
reported genetic correlations between disorders and the normal range of personality 
variation (e.g. 51) and support the view that some disorders are the extreme of a continuous 
trait in the population 52, 53. Genomic studies are also questioning the idea that psychiatric 
conditions are discrete entities by demonstrating substantial molecular genetic 
correlations across diagnostic categories and between disorders and normal ranges of 
phenotypic variation in the population54-57.  In some cases, these findings challenge 
fundamental assumptions of our clinical nosology. For example, the separation of 
schizophrenia and bipolar disorder has been a foundational distinction for psychiatric 
classification, dating to Kraepelin’s work more than a century ago. The modern DSM 
defines these disorders as mutually exclusive, belonging to different classes of mental 
illness. However, genomic studies have shown that, at a genetic level, these conditions are 
highly overlapping, with a genetic correlation of nearly 0.70.  
Taken together, genetic findings suggest that the structure of much psychopathology is 
defined by dimensional variation in the population, as is the case for hypertension and 
hypercholesterolemia, where the same genes often contain variants that cause diagnosable 
disorders and other variants that impact on variation in the “normal” range. By contrast, 
schizophrenia may be more complex as the disorder may represent a concatenation of 
several dimensions of risk including liability to psychosis, cognitive difficulties and social 
dysfunction.  Although diagnostic categories will continue to be needed from a practical 
standpoint, future iterations of psychiatric nosology may be usefully informed and refined 
by incorporating our emerging understanding of the etiologic overlap among clinical 
syndromes. This is, indeed, a premise of NIMH’s nascent Research Domain Criteria (RDoC) 
initiative 58. A former NIMH Director created controversy when he described the DSM as 
lacking validity and that NIMH would be “re-orienting its research away from DSM 
categories” 59. Others (e.g. 60) have called for a shift from what Kendler61 called the ‘soft’ 
symptom-based, etiologically blind diagnoses of the DSM to ‘hard’ diagnoses based on 
etiologically based biological features. Will genetic data lead to ‘hard’ empirically derived 
diagnoses? In isolation, probably not, but they, and mechanisms learned from them, may 
aid in the revision or formulation of novel diagnostic criteria in the future. They may also 
suggest novel hypotheses about the biological basis of psychiatric disorders. For example, a 
recent large genomic analysis found substantial genetic correlations between anorexia 
nervosa and a range of metabolic traits (including measures of cholesterol and lipids, 
fasting insulin, fasting glucose, insulin resistance, and leptin levels), suggesting that the 
disorder might be both a psychiatric and metabolic syndrome. 62 
The idea that genetic data should inform diagnostic nosologies is not new. Robins and 
Guze63 included family history as one criterion of a validation method that stimulated the 
design of structured diagnostic criteria. Kendler 64 cautioned that purely data-driven 
scientific nosologies could not address fundamental issues facing nosologists; e.g., how to 
integrate information from different types of “validators”.  Tsuang et al.65 suggested that 
psychiatric genetics could play a limited role by creating a nosology for genetic research 
aimed at better defining distinct genetic entities. Although such approaches are useful for 
researchers, the idea that psychiatric genetic findings will revolutionize the clinical 
psychiatric nosology has been questioned66.  This view suggests that, rather than leading to 
breakthroughs in genetic nosology, genetic data will, as it has in the past, incrementally 
help the DSM evolve via a process that Kendler 67 described as ‘epistemic iteration,’ 
whereby the evidence base sequentially iterates with the acquisition of new data to provide 
a better approximation of the latent, but unknown, structure of psychopathology. 
Alternatively, a more data-driven DSM process might consider a revolutionary recasting of 
diagnostic categories as dimensional entities with well-defined thresholds demarcating 
wellness from subthreshold and clinically significant disorders. This would provide 
clinicians the categories they need within a framework that better corresponds to the 
latent structure of psychopathology. However, the study of risk genes, which impact only 
on the liability to illness, will not, of itself, permit us to empirically define the boundaries 
between illness and health or between closely related disorders. Doing so would require 
including other empirical evidence regarding both diagnostic validity and clinical utility.  
Genetic complexity is a challenge for identifying clinically relevant biomarkers.  
In 1980, when DSM-III was released, 21 papers were published on biomarkers in 
psychiatry. Thirty-five years later, that number had grown to 1,555. This search for 
objective measures for defining disorders and their underlying pathophysiological 
processes reflects the field’s growing discomfort with the subjectively assessed signs and 
symptoms that define DSM disorders.  Although a Google patent search yields over 8,000 
relevant patents, with the exception of mutations causing rare, syndromal forms of 
psychiatric disorders and some useful genetic predictors of pharmacokinetics, this 
intensive search for biomarkers has not been impacted clinical practice.  
Genomic studies indicate that there are many causal genes and pathways, which implies 
that there will be many peripheral markers of disease, as has been shown for ADHD68. This 
suggests that multifactorial biomarkers will be needed.  Initial attempts to do this with 
genomic studies (e.g. 69) have been intriguing, but their interpretation is clouded by 
methodological concerns70. Thus, the current use of biomarkers to aid in diagnosis or 
genetic counseling in psychiatry has been limited to rare syndromic forms of disorders. In 
the future, PRS may become useful biomarkers if their precision and predictive value can 
be improved.  By aggregating genetic effects across many genes (and, indirectly, biological 
pathways) improved PRS may provide an informative summary marker despite the 
underlying genetic complexity.  
Where Do We Go From Here? 
The first and most obvious agenda for future research is to pursue ever-larger 
genomewide common and rare variant studies of psychiatric disorders. Empirical evidence 
and simulations show that for GWAS there is a sample-size-dependent inflection point 
beyond which the number of genomewide significant loci increases linearly. 71 For SCZ, the 
inflection point was seen at about 15,000 cases, but for other, perhaps more complex or 
heterogenous disorders such as MDD and SUDs, the inflection point may not be reached 
until as many as 75,000 to 100,000 cases are examined. 71 The numbers needed depend on 
a phenotype’s heritability and polygenicity and the effect sizes of the contributing SNPs 72. 
In the case of rare variants, effect sizes may be larger, but their rarity again requires large 
sample sizes (more than 25,000 cases) to allow detection of a sufficient number of risk 
variant carriers. 73, 74 The third wave of the PGC (PGC3), now underway, aims to enable this 
next generation of larger-scale GWAS and pathway analyses. 75 Currently, the PGC 
encompasses ten disorders and aims for 100,000 cases each. Though some have questioned 
the value of continuing to pursue larger GWAS, the evidence to date for psychiatric 
disorders and other complex diseases suggests that such efforts will continue to be 
important for identifying additional genes and through them the biological pathways that 
underlie disease. This will provide a foundation for novel diagnostic and therapeutic 
approaches, and for realizing the hope for personalized treatment. 17, 76 
Expanding the size and scope of genomewide common and rare variant studies will also 
help elucidate the genetic architecture of disorder-specific and cross-disorder genetic 
effects. Ongoing analyses by the PGC Cross-Disorder Workgroup are focusing on 
characterizing the association and functional significance of specific variants and pathways 
related to the nine disorders enumerated above, as well as looking for pleiotropic effects of 
variants detected. In addition, the PGC3’s Brainstorm initiative is linking the PGC with 
other GWAS consortia to examine the genetic relationships among psychiatric disorders, 
neurologic disorders, and dimensional measures of personality, cognition, and brain 
structure and function. Initial Brainstorm analyses across 23 brain disorders (with a total N 
= 842, 820) indicate that genetic overlap is stronger among traditionally defined 
psychiatric disorders than among neurologic disorders (e.g. multiple sclerosis, stroke, 
migraine) or between psychiatric and neurologic disorders 77, supporting the clinical 
demarcation between neurologic and psychiatric disorders. The average genetic 
correlation based on genomewide SNP data was +0.21 among eight psychiatric disorders 
(autism spectrum disorder, schizophrenia, bipolar disorder, major depressive disorder, 
ADHD, anorexia nervosa, obsessive-compulsive disorder, and Tourette syndrome), 
substantially higher than that observed among the ten neurologic disorders (0.06). 
Schizophrenia showed broad sharing with the other psychiatric disorders while autism and 
Tourette syndrome appeared to be the most genetically distinct. Strikingly, none of the 
neurologic disorders were significantly genetically correlated with the psychiatric 
disorders with the exception of migraine. 77 However, the low genetic correlation between 
the psychiatric and neurologic disorders could in part result from diagnostic differences as 
the psychiatric disorders were assessed using symptoms and signs and the neurological 
disorders often utilized imaging and/or neurophysiologic measures. 
We can also now capitalize on growing resources in electronic health records (EHR) 
and population-based registries linked to genomic data to examine the pleiotropic effects of 
psychiatric genetic risk variants across the phenome. 78 For example, the eMERGE network, 
a consortium of biobanks linked to EHR data, and large-scale cohort studies like the UK 
Biobank 79, which recently released genomewide data for 500,000 participants, and the 
recently launched All of Us Program of the NIH Precision Medicine Initiative80, offer 
opportunities to conduct well-powered phenomewide association studies (“PheWas”) of 
common and rare variants. These analyses may reveal unexpected etiologic relationships 
between psychiatric and other diseases or traits.81 The All of Us Research Program seeks to 
collect broad and deep phenotypic data (using EHRs, mobile technologies, surveys, and 
biospecimens) along with genomic data in a longitudinal cohort of 1 million or more 
Americans, and will offer an even larger resource for testing hypotheses about the 
spectrum of genotype-phenotype relationships for medical and psychiatric illness.  
Longitudinal population-based cohorts with genomic data can identify trajectories of 
disorder risk and gene-environment interplay. 82 Therefore, the ability to recall 
participants in biobanks or large-scale cohorts for further deep phenotyping based on 
genotype is critical.  
To date, most genomic studies have been restricted to cross-sectional, case-control 
analyses. The focus has been on phenotypic characterization, with little emphasis on the 
collection of high quality information on critical environmental risk factors. A more 
complete understanding of the etiology and structure of psychopathology will require an 
understanding of how genetic and environmental risk factors act and interact across 
development. To answer these questions will require study designs that attend to 
environmental risks and/or take an explicitly developmental perspective. For example, 
when in human development do risk alleles and pathways exert their effects? 83, 84 Might 
some pathways confer risk to a broad vulnerability to psychopathology and others to more 
differentiated disorders? Are there sensitive periods of development when environmental 
risk factors act or interact more potently to confer risk? What are the molecular or cellular 
mechanisms by which genetic variation and environmental exposures confer risk over the 
lifespan? These and other questions may be addressed with data from epidemiological 
birth cohorts (e.g., the Avon Longitudinal Study of Parents and Children, ALSPAC85), 
population-based registries (e.g., those available in Scandinavian countries 86) as well as 
large cohorts consented for follow-up (e.g. the UK Biobank79, All of Us80)  
Polygenic methods (e.g. PRS) may capture more complex combinations of disorder-
specific and cross-disorder variants as indices of genetic vulnerability, and be very useful in 
longitudinal and developmental studies. The PGC3 analytic plan includes PRS analyses of 
nine disorders in a longitudinal sample of nearly 14,000 twins followed from age 9 to age 
24. PGC analyses will also examine how environmental exposures modify genetic risk (PRS 
x environment interaction studies) to influence risk of a range of disorders. Although 
allelic-additive models are the most impervious to model misspecification, it should 
ultimately be possible to account for additional missing heritability in psychiatry by 
appropriately modeling dominant and recessive alleles, as well as gene-gene and gene-
environment interactions.  
Incorporating data beyond the categorical diagnostic variables that have been the 
predominant focus of psychiatric genetic studies to date will allow better characterization 
of the structure of psychopathology. To this end, investigators are undertaking studies of 
dimensional traits (e.g., RDoC measures) and incorporating neuroimaging phenotypes that 
may identify genetic underpinnings of neural, cognitive, affective and social phenotypes 
that transcend diagnostic boundaries. For example, recent analyses have demonstrated 
genetic overlaps between psychiatric disorders and measures of brain structure, including 
shared genetic influences for schizophrenia and thickness of the left superior frontal gyrus, 
a region where thinning and volume loss have previously been associated with the disorder 
87. The international ENIGMA consortium has brought together genomic and brain imaging 
data for more than 30,000 individuals spanning a broad range of psychiatric disorders, 
enabling a growing catalogue of discoveries about the genetic basis of brain structure and 
function and their relationship to psychopathology. 88 Other studies have examined the 
genetic relationship between disorder and normal variation in quantitative traits. 42 For 
example, common and rare genetic variants associated with autism spectrum disorder 
influence dimensions of social cognition, cognition/intelligence, and communication 
abilities in the general population 54, 56. Similarly, genetic risk scores for ADHD predict 
attention problems in population-based samples of children 55.  
Efforts to dissect the fundamental intermediate phenotypes underlying risk of 
psychiatric disorder face important challenges. Most importantly, we still do not know 
which are the most relevant levels of analyses and which of the large number of possible 
intermediate traits are causally related to mental illness. The domains enumerated in the 
RDoC framework89 represent one of several possible approaches. Genetic data may help 
resolve the causal status of putative intermediate phenotypes. For example, a candidate 
intermediate phenotype for which robust genetic associations are known can be analyzed 
using Mendelian randomization (which uses the associated variants as instrumental 
variables) to determine whether it is causally linked to a disorder 90.  This approach has 
been used successfully in other areas, providing evidence, for example, that central 
adiposity is causally related to coronary heart disease while HDL is not. 91, 92 In the realm of 
psychiatry, recent analyses have suggested that cannabis use maybe a causal risk factor for 
schizophrenia. 93 Because this approach is biased when there is pleiotropy (which is 
widespread in psychiatric genetics), other methods that can evaluate causality in presence 
of genetic correlation may be needed. 94  
Finally, having a more complete understanding of the genetic basis of psychiatric 
disorders will allow us to determine whether genetic variation, in concert with other more 
traditional variables, can improve prediction of clinically relevant outcomes. To date, the 
variance explained by common and rare variants, individually or as aggregate genetic risk 
scores, has been insufficient to be clinically useful for diagnosis or for prediction of clinical 
course. An exception is autism spectrum disorder, where genetic evaluation, including 
testing for structural and rare mutations, is recommended as part of the diagnostic process 
by the American College of Medical Genetics and Genomics95. In general, genetic 
biomarkers will only be clinically useful if they add value or efficiency beyond established 
non-genetic diagnostic procedures or risk factor profiles. As the power and precision of 
polygenic risk profiles improve and as more powerful rare variant studies allow us to 
fractionate disorder heterogeneity, this may be achievable for some disorders. For 
example, recent analyses support the existence of autism spectrum disorder subtypes that 
differ by their genetic architecture96, 97. Specific, highly penetrant structural and rare exonic 
mutations may represent genetic subtypes of heterogeneous disorders. In addition, a more 
complete characterization of the pleiotropic effects of psychiatric risk variants may have 
implications for genetic counseling. Numerous rare structural and single nucleotide 
variants have already been shown to influence a range of psychiatric disorders98. This 
catalogue of pleiotropic variants is expected to increase as the PGC3 conducts whole-
genome sequencing analyses of pedigrees densely affected by multiple psychiatric 
disorders to identify rare variants of strong effect. Given the substantial co-morbidity and 
overlap in genetic contributions to psychiatric disorders, studies should invest in 
phenotyping across disorders. Some, such as substance use disorders and depression, 
likely contribute to many common medical diseases, so studies of those diseases (e.g., liver 
disease, heart disease, cancers) should also gather information on lifetime patterns of 
substance use, abuse and dependence and symptoms of depression. We will also need to 
convince funders that GWAS will lead to a better mechanistic understanding and, 
ultimately, better prevention and treatment. 
Conclusions 
A substantial and growing body of genetic research has begun to elucidate the 
underlying structure of psychopathology. Before the modern era of genomic research, 
family and twin studies demonstrated that all major psychiatric disorders aggregate in 
families and are heritable. Over the past decade, the success of large-scale genomic studies 
has confirmed several key principles: 1) psychiatric disorders are highly polygenic, 
reflecting the contribution of hundreds to thousands of common variants of small effect 
and rare (often de novo) SNVs and CNVs; 2) the delineation of disease mechanisms from 
variant discovery is a difficult problem that requires integrating genetic information across 
multiple levels of functional data from “omics” to neurobiology to clinical phenotypes; and 
3) genetic influences on psychopathology commonly transcend the diagnostic boundaries 
of our clinical DSM nosology. At the level of genetic etiology, there are no sharp boundaries 
between diagnostic categories or between disorder and normal variation. In the coming 
years, ever-larger studies incorporating DNA sequencing, environmental exposures, and 
phenome-wide analyses will facilitate a more granular understanding of the genetic 
etiology and phenotypic spectrum of mental illness. 
The highly interconnected nature of cellular networks in the brain suggests that many, 
perhaps most, variants that regulate or participate in these pathways have some non-zero 
effect across psychiatric disorders (a concept called “network pleiotropy” 76) Thus, as naïve 
single gene and oligogenic models for psychiatric disorders have been replaced by the 
reality of hundreds if not thousands of risk variants, the field is facing a problem of 
daunting complexity.  However, it is better to confront directly this challenging reality than 
comfort ourselves with unrealistically simplistic models. Improvements in our ability to 
link genetic variation to gene function, sort out signal from noise with evolving statistical 
methods, and build in vitro and in vivo biological models to explore the “curse of 
polygenicity” should help with the translation from molecular genetic discoveries into 
etiologic insights.  Progress might be slow, but molecular genetic methods remain one of 
our few tools that can provide us direct insight into etiological pathways that underlie the 
structure of psychopathology.  
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Figure Legend 
Figure 1. Methods commonly used to evaluate genetic overlap between phenotypes. 
A. At the DNA variant level, individual loci (e.g. SNPs, rare mutations, or CNVs) may show 
evidence of pleiotropic association with two (e.g. P1, P2) or more phenotypes. At the level of 
biological pathways, gene sets assigned to a pathway may be enriched in association 
signals beyond chance expectation across multiple phenotype (e.g. P1, P2, P3). B. Genetic 
risk scores (or polygenic risk scores, PRS) are developed in a “discovery“ GWAS sample and 
computed for each individual in an independent “target” sample. The genetic risk score for 
each individual (i) in the target sample is computed as the product of the number of risk 
alleles (X) at each SNP (j) multiplied by that SNP’s association effect size (βj) and summing 
over all SNPs. The left hand plot shows the distribution of genetic risk scores in cases and 
controls in an independent target set for the same phenotype as that of the discovery 
sample. To examine cross-phenotype overlap, the discovery risk score is applied to target 
samples of other phenotypes. The proportion of variance explained by the discovery GWAS 
(R2) for each target phenotype (e.g. P2, P3, P4). is shown in the plot on the right hand side. C. 
Genetic correlation between phenotypes (ranging from -1.0 to +1.0) can be estimated using 
multiple methods that compare genetic and phenotypic similarity among unrelated 
individuals. The figure shows a hypothetical genetic correlation matrix between multiple 
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Table 1. Heritability and Genetic Correlation Estimates for Selected Psychiatric Disorders 
 
 On the diagonal: Heritability estimates (and 95% CI) from pedigree/twin studies (lower, shaded orange) and genomewide SNP 
analyses (upper, shaded light blue). The SNP-based estimates reflect only the common variant component of heritability. Also 
shown are pairwise genetic correlations from pedigree/twin studies (below diagonal) and genomewide SNP analyses (above 
diagonal). Bolded entries: 95% CI does not include 0.0. ASD: autism spectrum disorder; ADHD: attention deficit-hyperactivity 
disorder; SCZ: schizophrenia; BD: bipolar disorder; MDD: major depressive disorder; AN: anorexia nervosa; OCD: obsessive-
compulsive disorder; PTSD: posttraumatic stress disorder; N/A: not available. Sources: †22, #43, +77, ^21, £ 99, *100, ¥101, &102, ! 
103, $104, ¶105, %106, @107, ¢108, √109. 
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